Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 source : Www.globenewswire.com save search
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
Published: 2022-07-10 (Crawled : 16:20) - globenewswire.com
NVO | News | $125.705 -2.28% 1.3M
|
Health Technology
| Email alert
Add to watchlist
haemophilia phase 3
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $731.46 -1.91% 700K
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.32 3.53% 460K
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Alamos Gold Announces Phase 3+ Expansion of Island Gold to 2,400 tpd, Driving a Larger, More Profitable Operation with Average Annual Gold Production of 287k oz, Industry Low All-in Sustaining Costs of $576/oz, and a 31% Increase in Net Present Value (“NPV”) to $2.0 Billion at $1,850/oz Gold
Published: 2022-06-28 (Crawled : 23:00) - globenewswire.com
AGI | $15.2 0.46% 320K
|
Non-Energy Minerals
|
| O: 2.87%
H: 2.65%
C: 1.54%
expansion profitable phase 3
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
Published: 2022-06-27 (Crawled : 13:20) - globenewswire.com
ADIL | News | $1.65 -2.94% 68K
|
Health Technology
|
| O: 9.24%
H: 0.0%
C: -5.38%
trial phase 3
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - globenewswire.com
MDGL | $215.21 -1.45% 52K
|
Health Technology
| Email alert
Add to watchlist
liver international nash phase 3
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Published: 2022-06-17 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 3.13%
H: 8.66%
C: 6.63%
sciences women lancet therapy publication phase 3
Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate
Published: 2022-06-16 (Crawled : 10:00) - globenewswire.com
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
covid-19 vaccine program update phase 3
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
Published: 2022-06-14 (Crawled : 01:00) - globenewswire.com
DVAX | $11.505 -2.17% 120K
|
Health Technology
|
| O: -5.45%
H: 3.46%
C: 0.67%
scb-2019 covid-19 clover mrna trial phase 3 vaccine
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
Published: 2022-06-10 (Crawled : 13:20) - globenewswire.com
ONCT | $8.765 470
|
Health Technology
|
| O: -5.67%
H: 0.0%
C: 0.0%
therapeutics phase 3
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Published: 2022-06-09 (Crawled : 07:00) - globenewswire.com
VRNA | $15.435 -0.99% 64K
|
Health Technology
|
| O: 2.05%
H: 0.6%
C: -13.68%
treatment pharma trial phase 3
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Published: 2022-06-07 (Crawled : 21:00) - globenewswire.com
DBVT | $0.68 950
|
Health Technology
|
| O: 19.61%
H: 0.0%
C: 0.0%
topline trial positive results phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-06-03 (Crawled : 12:00) - globenewswire.com
TGTX | $14.245 -0.03% 460K
|
Health Technology
|
| O: 5.63%
H: 11.62%
C: 6.54%
trials therapeutics presentation sclerosis phase 3 multiple sclerosis
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Published: 2022-05-31 (Crawled : 12:00) - globenewswire.com
AXSM | $72.17 -1.24% 82K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
Published: 2022-05-19 (Crawled : 00:00) - globenewswire.com
KRYS | News | $163.12 0.67% 35K
|
Health Technology
|
| O: 3.63%
H: 1.97%
C: 1.39%
biotech phase 3
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Published: 2022-05-19 (Crawled : 12:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 18.8%
H: 2.81%
C: -0.79%
pharma trial positive results phase 3
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
Published: 2022-05-06 (Crawled : 01:00) - globenewswire.com
SRNE | $0.015 56K
|
Health Technology
|
| O: -7.06%
H: 0.63%
C: -3.8%
sp-102 presentation phase 3
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 16:00) - globenewswire.com
ZLAB | $15.92 5.29% 130K
|
Health Technology
|
| O: -1.73%
H: 0.38%
C: -3.24%
ARGX | $373.785 -0.35% 66K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Published: 2022-05-02 (Crawled : 20:00) - globenewswire.com
APLS G | $49.2 0.99% 210K
|
Health Technology
|
| O: 2.39%
H: 4.58%
C: -0.87%
phase 3
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Published: 2022-04-30 (Crawled : 04:20) - globenewswire.com
TARS | $33.49 -0.65% 55K
|
Health Technology
| Email alert
Add to watchlist
tp-03 treatment topline trial review phase 3
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
LICN | $0.7885 40.8% 11M
|
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.